[HTML][HTML] Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I …
European Journal of Cancer, 2022 - Elsevier
Background Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
SP Lau, L Klaase, M Vink, J Dumas… - … journal of cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
SP Lau, L Klaase, M Vink, J Dumas… - European Journal of …, 2022 - ejcancer.com
Background Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
SP Lau, L Klaase, M Vink, J Dumas… - European Journal of …, 2022 - europepmc.org
Background Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study
SP Lau, L Klaase, M Vink… - European …, 2022 - scholarlypublications …
Background: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
[PDF][PDF] Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
SP Lau, L Klaase, M Vink, J Dumas… - European Journal of …, 2022 - pure.eur.nl
Background: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
[PDF][PDF] Autologous dendritic cells pulsed with allogeneic tumor cell lysate induce tumor-reactive T-cell responses in pancreatic cancer patients: a phase I study
SP Lau, L Klaase, M Vink, J Dumas… - … for Pancreatic Ductal …, 2023 - core.ac.uk
Background: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …
[PDF][PDF] Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
SP Lau, L Klaase, M Vink, J Dumas… - European Journal of …, 2022 - pure.eur.nl
Background: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis
even after curative resection. Responses to immunotherapy are rare and related to …
even after curative resection. Responses to immunotherapy are rare and related to …